The third implementation report assesses international challenges and progress towards the 100 Days Mission (100DM) for pandemic preparedness in 2023. Despite progress being made in vaccines R&D including the first FDA-approved Chikungunya vaccine and Phase 1 trials for Crimean-Congo Haemorrhagic Fever (CCHF) vaccines, a concerning lack of investment in the R&D pipeline overall and signs of waning focus on pandemic preparedness are highlighted.
Key Recommendations:
- Greater coordination and investment in the therapeutics pipeline, to operationalise the 100DM Therapeutics Roadmap.
- Sufficient funding to implement the 100DM diagnostics framework, including supporting FIND’s initial ask of US$80-100m.
- Greater regulatory alignment and adoption of preparatory regulatory approaches.
- Strengthening of sustainable regional and global clinical trial infrastructure.